Friday, August 22, 2025
HomeTagsRead Magazine

Read Magazine

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors

Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced it has signed a...

Palo Alto Networks joins the Nasdaq-100

Palo Alto Networks the global cybersecurity leader, shared that it has joined the Nasdaq-100® Index, the top 100 largest domestic and international non-financial companies...

Lavie Bio Reports Advancement in its Bio-Fungicide Program for Fruit Rots

Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction of microbiome-based products, and...

Proterra announces EV battery factory in South Carolina as demand for commercial electric vehicles grows

As demand for commercial electric vehicles continues to grow across the United States and around the world, Proterra Inc, a leading innovator in commercial...

Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, announced that the New Zealand Medicines...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics